6 May 2010
EMA/HMPC/587580/2009
Committee on Herbal Medicinal Products (HMPC)

List of references supporting the assessment of *Tanacetum parthenium* (L.) Schulz Bip.

Tanaceti parthenii herba

(Feverfew)

Draft

The Agency acknowledges that copies of the underlying works used to produce this monograph were provided for research only with exclusion of any commercial purpose.

Abourashed EA, Khan IA. GC determination of parthenolide in feverfew products. Pharmazie 2001; 56: 971-2.

Anderson D, Jenkinson PC, Dewdney RS, Blowers SD, Johnson ES, Kadam NP. Chromosomal aberrations and sister chromatid exchanges in lymphocytes and urine mutagenicity of migraine patients: a comparison of chronic feverfew users and matched non-users. Hum Toxicol 1988; 7: 145-52.

Anderson KN, Bejcek BE. Parthenolide induces apoptosis in glioblastomas without affecting NF-kappaB. J Pharmacol Sci 2008; 106: 318-20.

Bamford CC, Tepper SJ. Daily pharmacologic prophylaxis of episodic migraine. Techniques in Regional Anesthesia and Pain Management 2009; 13: 20-27.

Barsby RW, Knight DW, McFadzean I. A chloroform extract of the herb feverfew blocks voltage-dependent potassium currents recorded from single smooth muscle cells. J Pharm Pharmacol 1993; 45: 641-5.

Barsby RW, Salan U, Knight DW, Hoult JR. Feverfew extracts and parthenolide irreversibly inhibit vascular responses of the rabbit aorta. J Pharm Pharmacol 1992; 44: 737-40.

Bejar E. Parthenolide inhibits the contractile responses of rat stomach fundus to fenfluramine and dextroamphetamine but not serotonin. J Ethnopharmacol 1996; 50: 1-12.

Brown AM, Edwards CM, Davey MR, Power JB, Lowe KC. Pharmacological activity of feverfew (Tanacetum parthenium (L.) Schultz-Bip.): assessment by inhibition of human polymorphonuclear leukocyte chemiluminescence in-vitro. J Pharm Pharmacol 1997; 49: 558-61.

7 Westferry Circus • Canary Wharf • London E14 4HB • United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7051
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Capasso F. The effect of an aqueous extract of Tanacetum parthenium L. on arachidonic acid metabolism by rat peritoneal leucocytes. J Pharm Pharmacol 1986; 38: 71-2.

Chen CF, Leung AY. Gene response of human monocytic cells for the detection of antimigraine activity of feverfew extracts. Can J Physiol Pharmacol 2007; 85: 1108-15.

Cutlan AR, Bonilla LE, Simon JE, Erwin JE. Intra-specific variability of feverfew: correlations between parthenolide, morphological traits and seed origin. Planta Med 2000; 66: 612-7.

Awang DVC. Prescribing therapeutic feverfew (*Tanacetum parthenium* (L.) Schultz bip., syn. Chrysanthemum parthenium (L.) Bernh.). Elsevier Science Inc. 1998; 1(1): 11-3

Diener HC, Pfaffenrath V, Schnitker J, Friede M, Henneicke-von Zepelin HH. Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention--a randomized, double-blind, multicentre, placebo-controlled study. Cephalalgia 2005; 25: 1031-41.

Heptinstall S.: Feverfew - an ancient remedy for modern times? (Editorial). Journal of the Royal Society of Medicine 1988; 81: 373.

Ernst E, Pittler MH. The efficacy and safety of feverfew (Tanacetum parthenium L.): an update of a systematic review. Public Health Nutr 2000; 3: 509-14.

EUROPEAN PHARMACOPOEIA 6th edition FEVERFEW Tanaceti parthenii herba 01/2008:1516

Fukuda K, Hibiya Y, Mutoh M, et al. Inhibition by parthenolide of phorbol ester-induced transcriptional activation of inducible nitric oxide synthase gene in a human monocyte cell line THP-1. Biochem Pharmacol 2000; 60: 595-600.

Groenewegen WA, Heptinstall S. A comparison of the effects of an extract of feverfew and parthenolide, a component of feverfew, on human platelet activity in-vitro. J Pharm Pharmacol 1990; 42: 553-7.

Groenewegen WA, Knight DW, Heptinstall S. Progress in the medicinal chemistry of the herb feverfew. Prog Med Chem 1992; 29: 217-38.

Gromek D, Kisiel W, Stojakowska A, Kohlmunzer S. Attempts of chemical standardizing of Chrysanthemum parthenium as a prospective antimigraine drug. Pol J Pharmacol Pharm 1991; 43: 213-7.

Guin JD, Skidmore G. Compositae dermatitis in childhood. Arch Dermatol 1987; 123: 500-2.

Guzman ML, Rossi RM, Karnischky L, et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 2005; 105: 4163-9.

Hausen BM, Osmundsen PE. Contact allergy to parthenolide in Tanacetum parthenium (L.) Schulz-Bip. (feverfew, Asteraceae) and cross-reactions to related sesquiterpene lactone containing Compositae species. Acta Derm Venereol 1983; 63: 308-14.

Hay AJ, Hamburger M, Hostettmann K, Hoult JR. Toxic inhibition of smooth muscle contractility by plant-derived sesquiterpenes caused by their chemically reactive alpha-methylenebutyrolactone functions. Br J Pharmacol 1994; 112: 9-12.

Hayes NA, Foreman JC. The activity of compounds extracted from feverfew on histamine release from rat mast cells. J Pharm Pharmacol 1987; 39: 466-70.

Hendricks H, Anderson-Wildeboer Y, Engels G, Bos R, Woerdenbag HJ. The content of parthenolide and its yield per plant during the growth of Tanacetum parthenium. Planta Med 1997; 63: 356-9.

Heptinstall S, Awang DV, Dawson BA, Kindack D, Knight DW, May J. Parthenolide content and bioactivity of feverfew (Tanacetum parthenium (L.) Schultz-Bip.). Estimation of commercial and authenticated feverfew products. J Pharm Pharmacol 1992; 44: 391-5.

Heptinstall S, White A, Williamson L, Mitchell JR. Extracts of feverfew inhibit granule secretion in blood platelets and polymorphonuclear leucocytes. Lancet 1985; 1: 1071-4.

Hwang D, Fischer NH, Jang BC, Tak H, Kim JK, Lee W. Inhibition of the expression of inducible cyclooxygenase and proinflammatory cytokines by sesquiterpene lactones in macrophages correlates with the inhibition of MAP kinases. Biochem Biophys Res Commun 1996; 226: 810-8.

Izumi E, Morello LG, Ueda-Nakamura T, et al. Trypanosoma cruzi: antiprotozoal activity of parthenolide obtained from Tanacetum parthenium (L.) Schultz Bip. (Asteraceae, Compositae) against epimastigote and amastigote forms. Exp Parasitol 2008; 118: 324-30.

Jin P, Madieh S, Augsburger LL. The solution and solid state stability and excipient compatibility of parthenolide in feverfew. AAPS Pharm Sci Tech 2007; 8: E105.

Johnson ES, Kadam NP, Hylands DM, Hylands PJ. Efficacy of feverfew as prophylactic treatment of migraine. Br Med J (Clin Res Ed) 1985; 291: 569-73.

Kalodera Z, Pepeljnjak S, Blazevic N, Petrak T. Chemical composition and antimicrobial activity of Tanacetum parthenium essential oil. Pharmazie 1997; 52: 885-6.

Kang BY, Chung SW, Kim TS. Inhibition of interleukin-12 production in lipopolysaccharide-activated mouse macrophages by parthenolide, a predominant sesquiterpene lactone in Tanacetum parthenium: involvement of nuclear factor-kappaB. Immunol Lett 2001; 77: 159-63.

Kang SN, Kim SH, Chung SW, Lee MH, Kim HJ, Kim TS. Enhancement of 1 alpha,25-dihydroxyvitamin D(3)-induced differentiation of human leukaemia HL-60 cells into monocytes by parthenolide via inhibition of NF-kappa B activity. Br J Pharmacol 2002; 135: 1235-44.

Killoran CE, Crawford GH, Pedvis-Leftick A. Two cases of compositae dermatitis exacerbated by moisturizer containing feverfew. Dermatitis 2007; 18: 225-9.

Kisiel W, Stojakowska A. A Sesquiterpene coumarin ether from transformed roots of Tanacetum Parthenium. Phytochemistry 1997; 46: 515-6.

Knight DW. Feverfew: chemistry and biological activity. Nat Prod Rep 1995; 12: 271-6.

Kwok BH, Koh B, Ndubuisi MI, Elofsson M, Crews CM. The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chem Biol 2001; 8: 759-66.

Loesche W, Groenewegen WA, Krause S, Spangenberg P, Heptinstall S. Effects of an extract of feverfew (Tanacetum parthenium) on arachidonic acid metabolism in human blood platelets. Biomed Biochim Acta 1988; 47: 241-3.

Loesche W, Mazurov AV, Voyno-Yasenetskaya TA, Groenewegen WA, Heptinstall S, Repin VS. Feverfew-an antithrombotic drug? Folia Haematol Int Mag Klin Morphol Blutforsch 1988; 115: 181-4.

Long C, Sauleau P, David B, et al. Bioactive flavonoids of Tanacetum parthenium revisited. Phytochemistry 2003; 64: 567-9.

Maizels M, Blumenfeld A, Burchette R. A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. Headache 2004; 44: 885-90.

Martin K, Sur R, Liebel F, et al. Parthenolide-depleted Feverfew (Tanacetum parthenium) protects skin from UV irradiation and external aggression. Arch Dermatol Res 2008; 300: 69-80.

Milbrodt M, Schröder F, König W. 3,4-β-Epoxy-8-Deoxycumambrin B, a sesquiterpene lactone from Tanacetum Parthenium. Phytochemistry 1997; 44: 471-4.

Mittra S, Datta A, Singh SK, Singh A. 5-Hydroxytryptamine-inhibiting property of Feverfew: role of parthenolide content. Acta Pharmacol Sin 2000; 21: 1106-14.

Murch SJ, Simmons CB, Saxena PK. Melatonin in feverfew and other medicinal plants. Lancet 1997; 350: 1598-9.

Murphy JJ, Heptinstall S, Mitchell JR. Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet 1988; 2: 189-92.

Naveen K. Jain, Shrinivas K. Kulkarni .Antinociceptive and anti inflammatory effects of Tanacetum parthenium L. extract in mice and rats. Journal of Ethnopharmacology 1999; 68: 251–59.

Nelson MH, Cobb SE, Shelton J. Variations in parthenolide content and daily dose of feverfew products. Am J Health Syst Pharm 2002; 59: 1527-31.

O'Neill LA, Barrett ML, Lewis GP. Extracts of feverfew inhibit mitogen-induced human peripheral blood mononuclear cell proliferation and cytokine mediated responses: a cytotoxic effect. Br J Clin Pharmacol 1987; 23: 81-3.

Pajak B, Orzechowski A, Gajkowska B. Molecular basis of parthenolide-dependent proapoptotic activity in cancer cells. Folia Histochem Cytobiol 2008; 46: 129-35.

Parada-Turska J, Mitura A, Brzana W, Jablonski M, Majdan M, Rzeski W. Parthenolide inhibits proliferation of fibroblast-like synoviocytes in vitro. Inflammation 2008; 31: 281-5.

Parada-Turska J, Paduch R, Majdan M, Kandefer-Szerszen M, Rzeski W. Antiproliferative activity of parthenolide against three human cancer cell lines and human umbilical vein endothelial cells. Pharmacol Rep 2007; 59: 233-7.

Pattrick M, Heptinstall S, Doherty M. Feverfew in rheumatoid arthritis: a double blind, placebo controlled study. Ann Rheum Dis 1989; 48: 547-9.

Paulsen E, Christensen LP, Andersen KE. Compositae dermatitis from airborne parthenolide. Br J Dermatol 2007; 156: 510-5.

Pfaffenrath V, Diener HC, Fischer M, Friede M, Henneicke-von Zepelin HH. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis--a double-blind, multicentre, randomized placebo-controlled dose-response study. Cephalalgia 2002; 22: 523-32.

Piela-Smith TH, Liu X. Feverfew extracts and the sesquiterpene lactone parthenolide inhibit intercellular adhesion molecule-1 expression in human synovial fibroblasts. Cell Immunol 2001; 209: 89-96.

Pittler MH, Ernst E. Feverfew for preventing migraine. Cochrane Database Syst Rev 2004; Issue 1. Art. No: CD002286.

Pryse-Phillips WE, Dodick DW, Edmeads JG, et al. Guidelines for the nonpharmacologic management of migraine in clinical practice. Canadian Headache Society. CMAJ 1998; 159: 47-54.

Rateb MEM, El-Gendy A-NAM, El-Hawary SS, El-Shamy AM. Phytochemical and biological investigation of Tanacetum parthenium (L.) cultivated in Egypt. J Med Plant Res 2007; 1: 018-26.

Reuter U, Chiarugi A, Bolay H, Moskowitz MA. Nuclear factor-kappaB as a molecular target for migraine therapy. Ann Neurol 2002; 51: 507-16.

Ross JJ, Arnason JT, Birnboim HC. Low concentrations of the feverfew component parthenolide inhibit in vitro growth of tumor lines in a cytostatic fashion. Planta Med 1999; 65: 126-9.

Sharma VK, Sahoo B. Prurigo-nodularis-like lesion in parthenium dermatitis. Contact Dermatitis 2000; 42: 235.

Shrivastava R, Pechadre JC, John GW. Tanacetum parthenium and Salix alba (Mig-RL) combination in migraine prophylaxis: a prospective, open-label study. Clin Drug Investig 2006; 26: 287-96.

Sumner H, Salan U, Knight DW, Hoult JR. Inhibition of 5-lipoxygenase and cyclo-oxygenase in leukocytes by feverfew. Involvement of sesquiterpene lactones and other components. Biochem Pharmacol 1992; 43: 2313-20.

Taylor F.R., MD, FAHS. Lifestyle changes, dietary restrictions, and nutraceuticals in migraine prevention. Techniques in Regional Anesthesia and Pain Management 2009; 13: 28-37.

Tassorelli C, Greco R, Morazzoni P, Riva A, Sandrini G, Nappi G. Parthenolide is the component of tanacetum parthenium that inhibits nitroglycerin-induced Fos activation: studies in an animal model of migraine. Cephalalgia 2005; 25: 612-21.

Thakkar JK, Sperelakis N, Pang D, Franson RC. Characterization of phospholipase A2 activity in rat aorta smooth muscle cells. Biochim Biophys Acta 1983; 750: 134-40.

Tiuman TS, Ueda-Nakamura T, Garcia Cortez DA, et al. Antileishmanial activity of parthenolide, a sesquiterpene lactone isolated from Tanacetum parthenium. Antimicrob Agents Chemother 2005; 49: 176-82.

Vogler BK, Pittler MH, Ernst E. Feverfew as a preventive treatment for migraine: a systematic review. Cephalalgia 1998; 18: 704-8.

WHO monographs 1998

Williams CA, Harborne JB, Geiger H, Hoult JR. The flavonoids of Tanacetum parthenium and T. vulgare and their anti-inflammatory properties. Phytochemistry 1999; 51: 417-23.

Won YK, Ong CN, Shen HM. Parthenolide sensitizes ultraviolet (UV)-B-induced apoptosis via protein kinase C-dependent pathways. Carcinogenesis 2005; 26: 2149-56.

Won YK, Ong CN, Shi X, Shen HM. Chemopreventive activity of parthenolide against UVB-induced skin cancer and its mechanisms. Carcinogenesis 2004; 25: 1449-58.

Wu C, Chen F, Rushing JW, et al. Antiproliferative activities of parthenolide and golden feverfew extract against three human cancer cell lines. J Med Food 2006; 9: 55-61.

Wu C, Chen F, Wang X, et al. Antioxidant constituents in feverfew (Tanacetum parthenium) extract and their chromatographic quantification. Food Chem 2006; 96: 220-7.

Wu C, Chen F, Wang X, et al. Identification of antioxidant phenolic compounds in feverfew (Tanacetum parthenium) by HPLC-ESI-MS/MS and NMR. Phytochem Anal 2007; 18: 401-10.

Yao H, Tang X, Shao X, Feng L, Wu N, Yao K. Parthenolide protects human lens epithelial cells from oxidative stress-induced apoptosis via inhibition of activation of caspase-3 and caspase-9. Cell Res 2007; 17: 565-71.

Yao M, Ritchie HE, Brown-Woodman PD. A reproductive screening test of feverfew: is a full reproductive study warranted? Reprod Toxicol 2006; 22: 688-93.

Zunino SJ, Ducore JM, Storms DH. Parthenolide induces significant apoptosis and production of reactive oxygen species in high-risk pre-B leukemia cells. Cancer Lett 2007; 254: 119-27.